Last reviewed · How we verify
PM01183
At a glance
| Generic name | PM01183 |
|---|---|
| Also known as | lurbinectedin |
| Sponsor | PharmaMar |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) (PHASE2)
- Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (PHASE1, PHASE2)
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) (PHASE3)
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) (PHASE3)
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC (PHASE1, PHASE2)
- A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (PHASE3)
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PM01183 CI brief — competitive landscape report
- PM01183 updates RSS · CI watch RSS
- PharmaMar portfolio CI